Dr. Hifzur R Siddique



    Assistant Professor


    Stem cells/ Cancer stem cells, non-coding RNAs, Therapy resistance cancer and Transgenesis


    207, Ibrahim Homes, Wadi-e-Ismail, Mafi, Dhorra, Aligarh, UP 202002





    Time Table


Resistance to therapy severely limits the effectiveness of chemotherapy drugs in treating cancer. For Advanced Cancer, the progression of tumors to the state of chemoresistance, the paucity of knowledge about the mechanism of chemoresistance, and the lack of therapeutic molecule/s are major stumbling blocks in managing and treating disease in cancer patients. Primary or acquired drug resistance remains a fundamental cause of therapeutic failure in cancer therapy. Since starting my research, I have been trying to understand how different cells, genes, and proteins might contribute to cancer's initiation, progression, and Chemoresistance. Unraveling drug resistance mechanisms and the discovery of new therapeutic molecule/s are not only facilitating rational treatment strategies to overcome existing limitations in therapeutic efficacy but will enhance biomarker discovery and the development of companion diagnostics. My laboratory has been investigating the role of cancer stem cells, transcription factor/ stem cell factor, and non-coding RNA in the process of primary and acquired chemoresistance using different in vitro models, animal models, and human clinical samples. I have published my work in Journals like (Hepatology, Impact Factor (IF)-17.5; Nature Communications (IF-17.7), Seminars in Cancer Biology (IF-17.1), Coordination Chemistry Reviews, IF-24.9; Clinical Cancer Research, IF-13.8; Cancer Research, IF-13.3; International J of Cancer, IF-7.4, Stem Cells, IF-6.3, Chemosphere (IF-9.0), ACS Applied Nanomaterials, IF-6.2; Life Sciences, IF-6.8, etc.). My research work is supported by the UGC-AMU-ICT grant, UGC, ICMR, and DST-SERB. Young investigators who have a keen research interest in Cancer Research and are interested in joining my Research Group as PDF, UGC-Kothari Fellow, CSIR-RA/SRA, Woman Scientist, etc. are well come to contact at

Patent: A Polyherbal Unani Formulation Majoon Suranjan Effective Against Cancer Cells Alone as well As in Combination with Anticancer Drug Sorafenib.

Patent No. 404151

Application No. 202011007071.

Patentee: 1. Deepti Singh 2. Mohammad Afsar Khan 3. Dr. Hifzur Rahman Siddique

Google Scholar citations

h-index-31;  i10 index-61;  Total Citations: 3210


  1. Science Direct

  2. PubMed

  3. Google Scholar

  1. Selected 20 Publications
    1. Singh D, Khan, MA, Siddique HR. 2024. Unveiling the Therapeutic Promise of Natural Products in Alleviating Drug-Induced Liver Injury (DILI): Present Advancements and Future Prospects. Phytotherapy Research. 38: 22-41. PMID: 37775996. Impact Factor- 7.2.
    2. Singh D, ……….., Siddique HR. 2024. Apigenin Enhances Sorafenib Anti-tumour Efficacy in Hepatocellular Carcinoma. Translational Oncology. 43: 101920. Impact Factor- 5.0
    3. Yeh DW*, Zhao X*, Siddique HR*, et al. 2023. MSI2 promotes translation of multiple IRES-containing oncogenes and virus to induce self-renewal of tumor initiating stem-like cells. Cell Death Discovery. 9: 141. PMID: 37117191. Impact Factor-7.1. *= Contributed Equally
    4. Fatma H, Siddique HR. 2023. Cancer Cell Plasticity, Stem Cell Factors and Therapy Resistance: How are they linked? Cancer and Metastasis Reviews. PMID: 37796391. Impact Factor- 9.2.
    5. Singh D, Siddique HR. 2023. Epithelial-to-mesenchymal transition in cancer progression: unraveling the immunosuppressive module driving therapy resistance. Cancer and Metastasis Reviews. PMID: 37775641. Impact Factor- 9.2.
    6. Fatma H, …, Siddique HR. 2023. Implication of Lupeol in compensating Sorafenib-Induced Perturbations of Redox Homeostasis: A Preclinical Study in Mouse Model. Life Sciences. 322: 121647PMID: 37011877 Impact Factor-6.1.
    7. Khan MA,……, Siddique HR. 2023. Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy. Toxicology and Applied Pharmacology. PMID: 37777120. Impact Factor- 4.0.
    8. Fatma H,… Siddique HR. 2022. Epigenetic Modifications of MYC: Role in Cancer Cell Reprogramming, Progression and Chemoresistance. Seminars in Cancer Biology. 83: 166-176 PMID: 33220458. Impact Factor-14.5.
    9. Khan MA, …., Siddique HR. 2022. Protective effect of Green Synthesized Selenium Nanoparticles Against Doxorubicin Induced Multiple Adverse Effects in Swiss Albino Mice. Life Sciences. 305: 120792. PMID: 35817167. Impact Factor-6.1. Impact Factor-6.1.
    10. Singh D, ……, Siddique HR. 2022. Apigenin in Cancer Prevention and Therapy: A Systematic Review and Meta-Analysis of Animal Models. Critical Reviews in Oncology/Hematology. 176: 10375. PMID: 35752426. Impact Factor-6.2.
    11. Singh D, .., Siddique HR. 2022. Apigenin Alleviates Cancer Drug Sorafenib Induced Multiple Toxic Effects in Swiss Albino Mice via anti-oxidative stress. Toxicology and Applied Pharmacology. 447: 116072. PMID: 35613639 Impact Factor- 4.
    12. Singh D, Khan MA, Siddique HR. 2022. Role of p53-miRNAs circuitry in immune surveillance and cancer development: A potential avenue for therapeutic intervention. Seminars in Cell and Developmental Biology. 24: 15-25. PMID: 33875349. Impact Factor-7.3.
    13. Farwa A, …., Siddique HR. 2021. Mechanochemical Synthesis of Sulfur Quantum Dots for Cellular Imaging. ACS Applied Nano Materials 4,4: 3339-3344. Impact Factor-6.0.
    14. Choi HY*, Siddique HR*, et al. 2020. p53 destabilizing protein skews asymmetric division and enhances NOTCH activation to direct self-renewal of TICs. Nature Communications.11: 3084  PMID: 32555153. Impact Factor-16.6. *= Contributed equally
    15. Jameel M, …….., Siddique HR. 2020. Interaction of thiamethoxam with DNA: Hazardous effect on biochemical and biological parameters of the exposed organism. Chemosphere. 254: 126875. PMID: 32361544 Impact Factor-8.8.
    16. Siddique HR, et al. 2015. NUMB Phosphorylation Destabilizes p53 and Promotes Self-renewal of Tumor-Initiating Cells by NANOG-dependent Mechanism in Liver Cancer. Hepatology. 62: 1466-1479. Impact Factor -13.5. PMID: 26174965.
    17. Siddique HR, Saleem M. 2012. Role of BMI1 in Cancer Recurrence and Chemoresistance: Preclinical and Clinical evidence. STEM CELLS 30: 372-378. PMID: 22252887. Impact factor-6.0.
    18. Siddique HR, et al. 2012. Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. International J. of Cancer. 131: 1720-31. PMID: 22190076. Impact factor -6.4.
    19. Siddique HR, et al. 2011. Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy. Clinical Cancer Research 17: 5379-91. PMID: 21712449. Impact factor -11.5.
    20.  Siddique HR, et al. 2005. Validation of Drosophila melanogaster as an in vivo model for genotoxicity assessment using the modified alkaline Comet assay. Mutagenesis 20: 285-290. PMID: 15899934. Impact factor-3.0

Genesis and Regeneration of Skeletal Muscle-6
Fibroblasts and their reformation-5
Regeneration and Repair
Cell Reprogramming of Stem Cells
Qualitative Aspects of Mutation-NonsenseTranscriptional Mutation-6
Splice sites, consensus sequence substitution and Mutation affecting Translation-7
Mechanism of Deletion & Insertion, Transposable Elements & Chromosome Mutations-8
Chromosomal Mutation-9
Chemistry of DNA Synthesis, DNA Self Propagation and Origin of Replication-8
Significance of Antiparallel arrangement, role of primer, exonuclease activity of DNA pol III-9
Significance of Antiparallel arrangement, role of primer, exonuclease activity of DNA pol III-10
DNA end replication-11